Finance

Beta
Lists
BMY:NYSE
Bristol-Myers Squibb Co
$54.40
+0.74%
(+0.40) 1D
Jun 22, 3:03:18 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMY...
Open
$54.20
High
$54.70
Low
$54.00
Mkt. cap
111.09B
Avg. vol.
11.61M
Volume
7.11M
Dividend
4.63%
Quarterly dividend
$0.63
Ex-dividend date
Jan 2, 2026
P/E ratio
15.27
52-wk high
$62.89
52-wk low
$42.52
EPS
$3.56
Beta
0.24
Shares outstanding
2.04B
No. of employees
32K
Open
$54.20
High
$54.70
Low
$54.00
Mkt. cap
111.09B
Avg. vol.
11.61M
Volume
7.11M
Dividend
4.63%
Quarterly dividend
$0.63
Ex-dividend date
Jan 2, 2026
P/E ratio
15.27
52-wk high
$62.89
52-wk low
$42.52
EPS
$3.56
Beta
0.24
Shares outstanding
2.04B
No. of employees
32K
Analyst outlook
Analyst Ratings
Based on 20 analysts giving stock ratings to BMY in the past 3 months
Buy
Buy
7
Hold
12
Sell
1
12 month forecast
Based on 20 Wall Street analysts offering 12 month price targets for BMY in the last 3 months.
Highest
Current $54.40
$75.00 (+37.87%)
Average
$63.13 (+16.05%)
Lowest
$40.00 (-26.47%)
News stories
From sources across the web
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Analyst Ratings
Based on 20 analysts giving stock ratings to BMY in the past 3 months
Buy
Buy
7
Hold
12
Sell
1
12 month forecast
Based on 20 Wall Street analysts offering 12 month price targets for BMY in the last 3 months.
Highest
Current $54.40
$75.00 (+37.87%)
Average
$63.13 (+16.05%)
Lowest
$40.00 (-26.47%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Courtney Breen
Bernstein
Hold
Maintained
-
-
06/09/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$72.00
+32.4%
06/05/2026
Michael Yee
UBS
Buy
Maintained
$70.00
+28.7%
06/03/2026
Emily Field
Barclays
Buy
Maintained
$75.00
+37.9%
06/02/2026
Unknown Analyst
Jefferies
Buy
Maintained
$73.00
+34.2%
06/01/2026
Louise Chen
Scotiabank
Hold
Maintained
$60.00
+10.3%
06/01/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$75.00
+37.9%
06/03/2026
Geoff Meacham
Citi
Hold
Maintained
$66.00
+21.3%
05/31/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$61.00
+12.1%
05/28/2026
Terence Flynn
Morgan Stanley
Sell
Maintained
$40.00
-26.5%
05/26/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$60.00
+10.3%
05/22/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$67.00
+23.2%
05/20/2026
Unknown Analyst
TD Cowen
Hold
Maintained
$57.00
+4.8%
05/18/2026
Evan Seigerman
BMO Capital
Hold
Maintained
$60.00
+10.3%
05/13/2026
Unknown Analyst
Berenberg Bank
Hold
Maintained
$60.00
+10.3%
05/08/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/01/2026
Trung Huynh
RBC Capital
Hold
Maintained
$60.00
+10.3%
04/30/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
04/30/2026
Carter Gould
Cantor Fitzgerald
Hold
Maintained
$54.00
-0.7%
04/08/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Rajesh Kumar
HSBC
Hold
Maintained
$60.00
+10.3%
03/17/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$65.00
+19.5%
01/28/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.58 / $1.42
+11.14%beat
Revenue / Est. (USD)
11.49B / 10.92B
+5.24%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
12.27B
12.22B
12.50B
11.49B
Cost of goods sold
3.36B
3.31B
3.51B
3.41B
Cost of revenue
3.36B
3.31B
3.51B
3.41B
Research and development expenses
2.26B
2.43B
2.56B
2.24B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
1.79B
2.09B
1.61B
Operating expense
4.78B
5.05B
5.47B
4.28B
Total operating expenses
8.14B
8.36B
8.98B
7.69B
Operating income
4.13B
3.86B
3.52B
3.80B
Other non operating income
399.00M
529.00M
544.00M
125.00M
EBT including unusual items
1.77B
3.11B
1.47B
3.24B
EBT excluding unusual items
4.22B
4.07B
3.86B
3.65B
Income tax expense
460.00M
919.00M
384.00M
561.00M
Effective tax rate
25.96%
29.51%
26.12%
17.32%
Other operating expenses
-
-
-
-
Net income
1.31B
2.20B
1.09B
2.68B
Net profit margin
10.68%
18.01%
8.69%
23.30%
Earnings per share
1.46
1.63
1.26
1.58
Interest and investment income
139.00M
161.00M
148.00M
104.00M
Interest expense
-485.00M
-482.00M
-432.00M
-406.00M
Net interest expenses
-346.00M
-321.00M
-284.00M
-302.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.12B
4.91B
4.54B
4.41B
Gain or loss from assets sale
-7.00M
-9.00M
-
-34.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer